Gabapentin Powder

Description

Gabapentin Powder

Background
Gabapentin capsules, tablets, and oral solution are used to help control certain types of seizures in people who have epilepsy. Gabapentin capsules, tablets, and oral solution are also used to relieve the pain of post-herpetic neuralgia (PHN; the burning, stabbing pain or aches that may last for months or years after an attack of shingles). Gabapentin extended-release tablets (Horizant) are used to treat restless legs syndrome (RLS; a condition that causes discomfort in the legs and a strong urge to move the legs, especially at night and when sitting or lying down). Gabapentin is in a class of medications called anticonvulsants. Gabapentin treats seizures by decreasing abnormal excitement in the brain. Gabapentin relieves the pain of PHN by changing the way the body senses pain (1).

Gabapentin is commercially available as 100mg, 300mg, and 400mg capsules and tablets, 600mg and 800mg tablets, and a 250mg/5 ml solution (2).

Regulatory Status
Gabapentin is FDA-approved in an oral formulation for the management of postherpetic neuralgia in adults and also as an adjunctive therapy in the treatment of partial onset seizures with and without secondary generalization in patients 12 years of age with epilepsy, and as adjunctive therapy in the treatment of partial onset seizures in pediatric patients age 3 to 12 years. Gabapentin is also indicated for treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults (2-3).
Gabapentin is recommended for add-on therapy in patients 3 years of age and older. Effectiveness in pediatric patients below the age of 3 years has not been established (2).

**Off-Label Uses:**
Off-label (non-FDA approved) compounded topical preparations of gabapentin have not been shown to be superior to commercially available topical diclofenac preparations.

**Related policies**
Gabapentin

**Policy**

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Gabapentin may be considered **medically necessary** in an oral formulation for the management of post-herpetic neuralgia, partial seizures epilepsy, or Restless Legs Syndrome (RLS) and if the conditions indicated below are met.

Gabapentin may be considered **investigational** for all other indications.

**Prior-Approval Requirements**

**Diagnoses**

Patient must have **ONE** of the following:

1. Postherpetic neuralgia
   a. 18 years of age or older

2. Partial seizure epilepsy
   a. Ages 3 -12 years of age
   b. Adjunctive therapy

3. Partial seizure epilepsy with or without secondary generalization
   a. 12 years of age or older
   b. Adjunctive therapy
4. Restless Legs Syndrome (RLS)
   a. 18 years of age or older

   AND ALL of the following:
   a. The requested dosage form is for oral use
   b. The requested dosage unit does not exceed the FDA approved dose of 800 mg/unit
   c. The requested dose is not commercially available

Prior – Approval Renewal Requirements
Same as above

Policy Guidelines
Pre - PA Allowance
None

Prior - Approval Limits
Duration  12 months

Prior – Approval Renewal Limits
Duration  12 months

Rationale

Summary
Gabapentin is FDA-approved in an oral formulation for the management of post-herpetic neuralgia in adults, as an adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients 12 years of age with epilepsy and as adjunctive therapy in the treatment of partial seizures in pediatric patient’s age 3 to 12 years. Gabapentin is also indicated for the treatment of Restless Legs Syndrome (RLS). There are no clinical studies to support the safety and effectiveness of gabapentin in a topical delivery system (1-3). Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of gabapentin while maintaining optimal therapeutic outcomes.

References
Section: Prescription Drugs  Effective Date: October 1, 2019
Subsection: Neuromuscular Drugs  Original Policy Date: June 20, 2013
Subject: Gabapentin Powder  Page: 4 of 4


Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2013</td>
<td>New addition to PA</td>
</tr>
<tr>
<td>September 2014</td>
<td>Annual criteria review and reference update</td>
</tr>
<tr>
<td>December 2015</td>
<td>Annual editorial review</td>
</tr>
<tr>
<td>December 2016</td>
<td>Annual editorial review and reference update</td>
</tr>
<tr>
<td></td>
<td>Policy number change from 5.15.01 to 5.75.13</td>
</tr>
<tr>
<td>September 2017</td>
<td>Annual editorial review and reference update</td>
</tr>
<tr>
<td>June 2018</td>
<td>Annual editorial review and reference update</td>
</tr>
<tr>
<td>September 2019</td>
<td>Annual review and reference update</td>
</tr>
</tbody>
</table>

Keywords

This policy was approved by the FEP Pharmacy and Medical Policy Committee on September 13, 2019 and is effective on October 1, 2019.